Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press118310.17650/1726-9776-2006-2-2-40-43DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряLong-term results of treatment for recurrent supercifial bladder carcinoma with “Imuron” BCG vaccineОтдаленные результаты лечения рецидивов поверхностного рака мочевого пузыря вакциной БЦЖ «Имурон»SafiullinK. N.СафиуллинК. Н.
Russian Federation

Obninsk

Обнинск

KaryakinO. B.КарякинО. Б.
Russian Federation

Obninsk

Обнинск

Medical Radiology Research Center, Russian Academy of Medical SciencesГУ Медицинский радиологический научный центр РАМН300620062240431802202018022020https://oncourology.abvpress.ru/oncur/article/view/1183

Intravesical immunotherapy with the BCG vaccine «Imuron» along with courses of maintenance therapy has been performed in 25 patients. During a more than 10-year follow-up, there are 20 (80%) survivors; of them 15 (75%) patients have no recurrences. The used treatment regimen is effective and allows a long monitoring of the disease with the good quality of life. The occurrence of recurrences in 5 (25%) patients in the late period of the follow-up (after 8-13.5 years) leads to the conclusion that patients should be long followed up by an oncourologist and undergo cytoscopic studies with photodynamic diagnosis.

.

1. Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2003 г. М. 2005.Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2003 г. М. 2005.2. Карякин О.Б. Факторы прогноза у больных поверхностным раком мочевого пузыря. Актуальные вопросы лечения онкоурологических заболеваний. Обнинск 1997.Карякин О.Б. Факторы прогноза у больных поверхностным раком мочевого пузыря. Актуальные вопросы лечения онкоурологических заболеваний. Обнинск 1997.3. Morales A., Eidinger D., Bruce A.W. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol (Baltimore) 1976;116:180—3.Morales A., Eidinger D., Bruce A.W. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol (Baltimore) 1976;116:180—3.4. Фигурин К.М. Клиническая онкоурология. М. 2003;271–93.Фигурин К.М. Клиническая онкоурология. М. 2003;271–93.5. Lamm D.L. Preventing progression and improving survival with BCG maintenance. Eur Urol 2000;37 (Suppl 1): 9—15.Lamm D.L. Preventing progression and improving survival with BCG maintenance. Eur Urol 2000;37 (Suppl 1): 9—15.6. Hanna M.G., De Iager R., Guinan P. et al. Bacillus Calmette-Guerin (BCG) vaccine for Tuberculosis: Antitumor effect in Experimental Animals and Humans. Vaccine Research 1992;1(2):69—91.Hanna M.G., De Iager R., Guinan P. et al. Bacillus Calmette-Guerin (BCG) vaccine for Tuberculosis: Antitumor effect in Experimental Animals and Humans. Vaccine Research 1992;1(2):69—91.7. Mitjes J.A.,Van der Meijden A.P. et al. A randomized prospective staid comparing intravesical instillations of Mitomycin – C, BCG TICE and BCG RIVM in pTa-pT1 tumors and primary carcinoma in situ of the urinary bladder. Eur J Cancer 1993;12:1672.Mitjes J.A.,Van der Meijden A.P. et al. A randomized prospective staid comparing intravesical instillations of Mitomycin – C, BCG TICE and BCG RIVM in pTa-pT1 tumors and primary carcinoma in situ of the urinary bladder. Eur J Cancer 1993;12:1672.